Search results for "Elisa method"

showing 4 items of 4 documents

Evaluation of TKTL1 as a biomarker in serum of prostate cancer patients.

2016

Introduction Monocyte associated transketolase-like 1 (TKTL1) as a cancer biomarker has become popular with alternative practitioners, but plays no role in conventional medicine. This investigation evaluates the potential of serum TKTL1 as a biomarker for prostate cancer. Material and methods Patients (n = 66) undergoing curative radical prostatectomy (RPE) for biopsy-pro-ven PCa were included in the study. Controls (n = 10) were healthy, age-matched, male volunteers. 10 ml of peripheral blood was drawn from patients several days before surgery and from controls. Serum TKTL1 was measured using the ELISA method. Results The median age at tumor diagnosis was 66 years and median serum PSA was …

Conventional medicineOncologymedicine.medical_specialtydiagnosismedicine.medical_treatmentTKTL102 engineering and technologyGastroenterology03 medical and health sciencesProstate cancer0302 clinical medicineInternal medicineTumor stagemedicinecomplementary medicineElisa methodOriginal PaperProstatectomybusiness.industryMonocyteGleason SumGeneral Medicine021001 nanoscience & nanotechnologymedicine.diseaseprostate cancerPeripheral bloodmedicine.anatomical_structure030220 oncology & carcinogenesisbiomarker0210 nano-technologybusinessCentral European journal of urology
researchProduct

Baseline seroepidemiology of hepatitis A virus infection among children and teenagers in Italy.

1991

During the period from May 1987 through November 1989, the prevalence of antibodies to hepatitis A virus infection (anti-HAV) was assayed by the ELISA method in the serum samples of 5,507 (54% males, 46% females) apparently healthy subjects three to 19 years old in Italy. Subjects were selected by a systematic cluster sampling in five different geographical areas of Italy. The overall prevalence of anti-HAV was 9.5%; it increased from 2.3% among children three to five-years-old to 16.3% in teenagers 17 to 19 years old (p less than 0.001). A slight preponderance of females was observed (10% versus 9.1%), but the difference was not statistically significant. The prevalence was significantly h…

Microbiology (medical)AdultMalemedicine.medical_specialtyAdolescentEnzyme-Linked Immunosorbent AssayAntibodies ViralSerologyEpidemiologyMedicineHumansHepatovirusElisa methodChildHepatitisbusiness.industryHealthy subjectsGeneral MedicineHepatitis Amedicine.diseaseHepatitis a virusYoung ageInfectious DiseasesEl NiñoItalySocioeconomic FactorsChild PreschoolImmunologyFemalebusinessDemographyInfection
researchProduct

Cerebrospinal fluid tau protein is not a biological marker in amyotrophic lateral sclerosis.

2009

Background:  Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disorder leading to progressive motor neuron cell death. Etiopathogenesis is still imperfectly known and much effort have been undertaken to find a biological marker that could help in the early diagnosis and in the monitoring of disease progression. Cerebrospinal fluid (CSF) concentrations of tau, an axonal microtubule-associated protein, have been measured in ALS with levels found increased in some studies and unchanged in others. Methods:  Total CSF tau level was assayed in a population of ALS patients (n = 57) and controls (n = 110) using a specific ELISA method. Results:  No significant differences in the median CS…

MaleProgrammed cell deathPathologymedicine.medical_specialtyTau proteinPopulationEnzyme-Linked Immunosorbent Assaytau Proteinscerebrospinal fluidtau proteinCerebrospinal fluiddisease progressionHumansMedicineamyotrophic lateral sclerosiAmyotrophic lateral sclerosisElisa methodeducationAgededucation.field_of_studybiologybusiness.industryAmyotrophic Lateral SclerosisDisease progressionMiddle AgedMotor neuronmedicine.diseasemedicine.anatomical_structureNeurologybiology.proteinamyotrophic lateral sclerosis cerebrospinal fluid disease progression tau proteinFemaleSettore MED/26 - NeurologiaNeurology (clinical)businessBiomarkers
researchProduct

Heparan sulfate levels in mucopolysaccharidoses and mucolipidoses.

2004

Glycosaminoglycans are accumulated in both mucopolysaccharidoses (MPS) and mucolipidoses (ML). MPS I, II, III and VII and ML II and ML III patients cannot properly degrade heparan sulphate (HS). In spite of the importance of HS storage in the metabolic pathway in these diseases, blood and urine HS levels have not been determined systematically using a simple and economical method. Using a new ELISA method using anti-HS antibodies, HS concentrations in blood and urine were determined in MPS and ML II and ML III patients. HS concentrations were determined in 156 plasma samples from MPS I (n = 23), MPS II (n = 26), MPS III (n = 24), MPS IV (n = 62), MPS VI (n = 5), MPS VII (n = 5), ML II (n = …

congenital hereditary and neonatal diseases and abnormalitiesAdolescentMucopolysaccharidosisEnzyme-Linked Immunosorbent AssayUrineSignificant elevationGlycosaminoglycanchemistry.chemical_compoundMucolipidosesGeneticsmedicineHumansElisa methodskin and connective tissue diseasesChildGenetics (clinical)Chromatography High Pressure LiquidGlycosaminoglycansDose-Response Relationship DrugChemistryHeparinInfant Newbornnutritional and metabolic diseasesMucolipidosesInfantHeparan sulfateMucopolysaccharidosesmedicine.diseaseMolecular biologyDose–response relationshipBiochemistryChemistry ClinicalChild PreschoolHeparitin SulfateBiomarkersJournal of inherited metabolic disease
researchProduct